



PHARMACEUTICAL 2020











RealRate

PHARMACEUTICAL 2020



ANAPTYSBIO INC Rank 78 of 362

The relative strengths and weaknesses of ANAPTYSBIO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANAPTYSBIO INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 186% points. The greatest weakness of ANAPTYSBIO INC is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 22%, being 325% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	377,733
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	29,535
Liabilities, Non-Current	0
Other Assets	55,846
Other Compr. Net Income	561
Other Expenses	-152
Other Liabilities	0
Other Net Income	9,944
Property and Equipment	1,618
Research and Development	99,338
Revenues	8,000
Selling, General and Administrative Expense	16,094

Output Variable	Value in 1000 USD
Assets	435,197
Liabilities	29,535
Expenses	115,280
Stockholders Equity	405,662
Net Income	-97,336
Comprehensive Net Income	-97,056
Economic Capital Ratio	22%

